Unit 3: Advanced Pharmaceutical Excipients (Part II)

Semester 8

BP813T

Advanced Pharmaceutical Excipients (Part II)

Moving from liquids to solids, this unit investigates the advanced excipients required to build robust tablets, capsules, and highly sophisticated Novel Drug Delivery Systems (NDDS). It covers the massive industrial shift towards ‘Direct Compression’ vehicles (saving immense manufacturing time), the specific functional polymers used to coat tablets (Enteric and Sustained Release), and the highly specialized, ultra-pure excipients necessary for sterile parenterals and inhalers.

Syllabus & Topics

1Tablet and Capsule Excipients: Diluents (Fillers): Provide bulk to API-doses that are too small to punch (<50mg). Ex: Lactose, Starch, MCC (Microcrystalline Cellulose), Mannitol (cool sensation for chewable tablets). Binders: Provide mechanical strength/cohesion to powders during granulation. Ex: PVP (Povidone), Starch paste, HPMC. Disintegrants: Ensure the tablet breaks apart rapidly upon hitting stomach fluid to allow dissolution. Ex: Crospovidone (superdisintegrant), Sodium Starch Glycolate. Lubricants & Glidants: Prevent the powder from sticking to the metal punches (Magnesium Stearate) and improve powder flow from the hopper (Talc, Colloidal Silicon Dioxide).
2Directly Compressible Vehicles: The Wet Granulation Problem: Traditional tablet manufacturing involves 7+ steps (mixing, wet massing, granulating, drying, milling). It is highly expensive, uses heat/moisture (degrading sensitive drugs), and takes days. Direct Compression: Mixing the API directly with highly specialized excipients and punching it instantly into a tablet. It requires ZERO heat or moisture. Directly Compressible Excipients MUST possess exceptional flowability and exceptional compressibility inherently. Key Examples: Microcrystalline Cellulose (MCC/Avicel – brilliant compressibility via plastic deformation). Spray-dried Lactose (spherical particles flow perfectly). Starch 1500 (pregelatinized starch).
3Functional Coat Materials: Purpose of Coating: Masking bitter taste, protecting drugs from stomach acid (Enteric), modifying drug release (Sustained/Controlled Release), and improving appearance/swallowability. Film Coating Polymers: HPMC (Hydroxypropyl methylcellulose) is the standard for non-functional, water-soluble protective coatings. Enteric Coating Polymers: Strictly designed to NEVER dissolve in the highly acidic stomach (pH 1.2), but dissolve instantly in the alkaline intestines (pH 6.8). Prevents stomach irritation (NSAIDs) or protects acid-sensitive drugs (Omeprazole). Key Examples: CAP (Cellulose Acetate Phthalate), Eudragit L & S (Methacrylic acid copolymers). Sustained-Release Polymers: Eudragit RL/RS, Ethylcellulose (water-insoluble film that slowly leaks the drug).
4Excipients for Parenterals and Aerosols: Parenteral (Injection) Excipients: MUST be absolutely sterile, pyrogen-free, and exactly isotonic with human blood plasma. Buffers (Citrate, Phosphate) to maintain pH. Isotonicity Modifiers (0.9% NaCl, Dextrose 5%) to prevent red blood cells from shrinking/bursting. Solvents (Water for Injection WFI, Sesame oil for Depot injections). Preservatives (Benzyl alcohol). Antioxidants (Sodium Metabisulfite for aqueous; BHT for oily). Aerosol Excipients: Used for MDI (Metered Dose Inhalers). Propellants generate pressure. CFCs (Freon) are banned due to ozone depletion; exclusively replaced with HFAs (Hydrofluoroalkanes). Corecipients include Sorbitan Trioleate (Span 85) to lubricate the inhaler valve.
5Excipients for Novel Drug Delivery Systems (NDDS): NDDS bypass traditional limitations by actively targeting the drug directly to the diseased tissue or precisely controlling its release over 24-72 hours. Liposomes: Microscopic artificial vesicles consisting of a spherical lipid bilayer (Phospholipids and Cholesterol). Used dramatically in oncology (Doxil/Doxorubicin formulation) to reduce cardiac toxicity. Biodegradable Polymers: PLGA (Polylactic-co-glycolic acid). The gold standard for implantable devices/microspheres. Slowly degrades into harmless lactic/glycolic acid in the body over months. Solid Lipid Nanoparticles (SLNs): Formulated using physiological lipids (triglycerides, waxes) that are solid at room and body temperature, improving the extremely low bioavailability of highly lipophilic drugs.

Learning Objectives

Differentiate Tablet Roles: Clearly distinguish between the functional role of a Binder (strength), a Disintegrant (break-apart), a Glidant (flow), and a Lubricant (anti-stick).

Explain the Advantages of Direct Compression: Detail the specific manufacturing benefits of skipping wet granulation and justify why Microcrystalline Cellulose (Avicel) is the premium directly compressible vehicle.

Define Enteric Coating Mechanisms: Describe how Cellulose Acetate Phthalate uniquely manipulates pH environments to protect gastric-sensitive APIs from concentrated stomach acid (pH 1.2).

List Key Parenteral Standards: Identify the three critical standards (Sterility, Pyrogen-free, Isotonicity) for injectable excipients and identify completely non-toxic isotonicity modifiers.

Assess the Efficacy of PLGA and Liposomes: Explain the precise mechanisms by which Liposomes target drug delivery, and how PLGA provides months-long sustained release inside the body.

Exam Prep Questions

Q1. Why do we add “Superdisintegrants” instead of regular starch to tablets?

Superdisintegrants are used because they provide rapid and efficient tablet disintegration at very low concentrations (2–4%). Unlike regular starch, which requires large amounts (up to 15%) and increases tablet size, superdisintegrants like crospovidone or sodium starch glycolate swell dramatically upon contact with water, causing the tablet to break apart quickly while keeping it compact and easy to swallow.

Q2. Why can’t I just crush an “Enteric-Coated” tablet?

Enteric-coated tablets are designed to resist stomach acid and release the drug only in the intestine. Crushing them destroys this protective coating, exposing the drug to gastric acid, which may degrade it or cause irritation to the stomach lining. This can reduce drug effectiveness or lead to adverse effects such as gastric irritation or ulcers, especially with drugs like NSAIDs.

Q3. What exactly is “PLGA” used for in Novel Drug Delivery Systems?

PLGA (polylactic-co-glycolic acid) is a biodegradable polymer widely used in controlled drug delivery systems. It is used to form microspheres or implants that release drugs slowly over time. As PLGA degrades into lactic acid and glycolic acid (natural metabolites), the drug is gradually released, allowing sustained therapeutic effects without the need for frequent dosing or surgical removal of the delivery system.